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Unfermented C. genistoides methanol extracts of different harvestings and selected polyphenols were
evaluated for phytoestrogenic activity by comparing binding to both ER subtypes, transactivation of
an ERE-containing promoter reporter, proliferation of MCF-7-BUS and MDA-MB-231 breast cancer
cells, and binding to SHBG. The extracts from one harvesting of C. genistoides (P104) bound to
both ER subtypes. All extracts transactivated ERE-containing promoter reporters via ERâ but not via
ERR. All extracts, except P122, caused proliferation of the estrogen-sensitive MCF-7-BUS cells.
Proliferation of MCF-7-BUS cells was ER-dependent as ICI 182,780 reversed proliferation. Physi-
ologically more relevant, extracts antagonized E2-induced MCF-7-BUS cell proliferation. Furthermore,
all extracts, except P122, induced proliferation of the estrogen-insensitive MDA-MB-231 cells,
suggesting that the extracts are able to induce ER-dependent and ER-independent cell proliferation.
Binding to SHBG by extracts was also demonstrated. These results clearly show that C. genistoides
methanol extracts display phytoestrogenic activity and act predominantly via ERâ. HPLC and LC-
MS analysis, however, suggests that the observed phytoestrogenic activity cannot be ascribed to
polyphenols known to be present in other Cyclopia species.
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INTRODUCTION
Cyclopia genistoides, a fynbos shrub, together with C.
subternata, C. intermedia, and to a lesser extent C. sessiliflora,
are commercially available as the fragrant caffeine-free hon-
eybush tea. Honeybush tea has already been identified as having
both antioxidant and antimutagenic activity, which adds value
to this herbal infusion (1). The presence of the known phy-
toestrogens, formononetin, eriodictyol, and naringenin, in C.
intermedia (2) and luteolin in both C. intermedia and C.
subternata (2, 3) plus anecdotal evidence that honeybush tea
helps alleviate menopausal symptoms led to the investigation
of putative phytoestrogenic activity in Cyclopia spp.
Phytoestrogens are plant polyphenols able to mediate weak
estrogenic or anti-estrogenic activity (4). Most research inves-
tigating phytoestrogens has concentrated on soybean and the
isoflavone, genistein, a well-documented phytoestrogen abun-
dantly present in soy (5). Epidemiological studies suggest that
an Asian diet rich in soy is protective against hormone-induced
cancers such as breast and prostate cancer (6-9). In addition,
phytoestrogens are thought to be useful for the treatment of
menopausal symptoms and to protect postmenopausal women
against cardiovascular disease and osteoporosis, without the risks
associated with traditional hormone replacement therapy (HRT)
(10-14). However, some studies have failed to show significant
alleviation of menopausal symptoms, such as hot flushes, while
other studies, although showing some efficacy, suggest that
phytoestrogen treatment is not as effective as traditional HRT
(15-17). Recently, the safety of long-term use of traditional
HRT has been questioned by several studies (18-20). This and
the general increase in popularity of natural medicine have lent
impetus to the search for and investigation into alternative
treatments (21).
A previous study by our group (22), which screened extracts
from the four commercially available Cyclopia species for
estrogenic activity through binding to the ER subtypes, identified
methanol extracts from C. genistoides as consistently having
the highest binding affinity for both ER subtypes.
The biological responses to estrogen are mediated mainly via
the estrogen receptor (ER) subtypes, ERR and ERâ (23). The
ERs are ligand-activated transcription factors (24) that dissociate
from heat shock proteins on activation by ligand. Activation
also involves a conformational change, which allows dimer-
ization and binding to estrogen response elements (EREs)
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situated in the promoter region of estrogen responsive genes
thereby activating or inhibiting transcription (23). Phytoestrogens
are able to compete with 17-â-estradiol (E2) for binding to the
ER subtypes and are able to act as either agonist or antagonist
when bound to the ERs (25). Phytoestrogens generally bind to
the ER subtypes with a much lower affinity than E2 and display,
unlike E2, a higher affinity for ERâ than for ERR (25, 26). In
addition, phytoestrogens have been shown to induce transacti-
vation via both ER subtypes (27), with an increased transcrip-
tional response through ERâ. They are, however, less potent
than E2 via both ER subtypes (27, 28).
Estrogens are responsible for the proliferation and differentia-
tion of a number of tissues (29), and this property is often used
to evaluate estrogenicity (30). Hyper-proliferation can cause or
enhance the spread of cancer (31). The ERâ subtype is believed
to be a negative modulator of ERR-mediated activity as it has
been demonstrated to inhibit transactivation and cell proliferation
when coexpressed with ERR (32-34). ERâ is thus believed to
be the natural cellular protective mechanism against excessive
cell proliferation mediated by ERR, and numerous studies
concentrate on compounds, such as phytoestrogens, which are
able to distinguish between the two ER subtypes with prefer-
ential binding to and/or transactivation via ERâ (33).
Estrogens circulating in the blood are transported primarily
bound to serum albumin or sex hormone-binding globulin
(SHBG) (35). Only unbound estrogens are able to diffuse across
the cell membrane and mediate an estrogenic response (36). It
has been suggested that phytoestrogens may alter the concentra-
tion of biologically active endogenous estrogens, by either
binding to SHBG and displacing bound estrogens or by
stimulating SHBG synthesis (37). It is thus clear that phy-
toestrogens not only have a direct effect on estrogen signaling
through binding to the ER subtypes, but also an indirect effect
through altering the concentrations of biologically active
estrogens.
In the present study, methanol extracts from C. genistoides
(Table 1) as well as known polyphenols present in Cyclopia
spp., which either were shown to bind to both ER subtypes
(luteolin, formononetin, and naringenin) or were present at very
high concentrations such as mangiferin, were further investigated
(Figure 1). Although useful as an initial screening technique,
binding to the ER subtypes alone does not distinguish agonist
from antagonist activity, and thus the present study extends the
initial investigation (22) by including a number of other in vitro
assays such as the transactivation of an ERE-containing
promoter reporter construct, cell proliferation of two breast
cancer cells, and binding to SHBG. In addition, HPLC and LC-
MS analysis was done on the specific methanol extracts
investigated to quantify and confirm the identity of the polyphe-
nols known to be present in other Cyclopia species.
MATERIALS AND METHODS
Test Compounds Used. 17-â-Estradiol, genistein, mangiferin, and
naringenin were purchased from Sigma-Aldrich (Cape Town, South
Africa), and luteolin and formononetin were from Extrasynthese (Genay,
France).
Dried Methanol Extract (DME) Preparation. Two methanol
extracts of unfermented C. genistoides were prepared from each of three
independent harvestings. The extraction was repeated to compare
different methanol extractions of the same plant material (Table 1).
Cyclopia genistoides plants were chosen randomly in a plantation, and
several bushes were harvested on each occasion. The harvested plant
material (Table 1), comprising intact stems and leaves, was dried whole
at 40 °C to less than 10% moisture content, whereafter it was milled
(1 mm sieve) and stored at room temperature in a sealed container.
Dried, pulverized, unfermented plant material (25 g) was extracted three
times with 50 mL of dichloromethane at room temperature for 20 h
each, filtered through Whatman No. 4 filter paper with a Buchner
funnel, and the filtrate was discarded. Thereafter, methanol extraction
(50 mL) of the air-dried plant material was performed twice at room
temperature for 20 h each. The methanol extracts were pooled with a
Table 1. Details of C. genistoides Plant Material Harvested, Dried Methanol Extracts (DMEs) Prepared from the Harvestings, and Extract Yield and
Total Polyphenol (TPP) Content of DMEs



























a The abbreviations used for the harvestings are also used for the dry methanol extracts (DMEs) prepared from these harvestings. Although all harvestings were done
on the same plantation, they were done at different times. Two extracts were prepared of each harvesting. b Yield ) g of freeze-dried extract per 100 g of dried pulverized
plant material. c TPP content ) g of gallic acid equiv per 100 g of of freeze-dried extract. d First methanol extract of the same harvesting. e Second methanol extract of
the same harvesting (prepared at a later stage).
Figure 1. Chemical structures of the plant polyphenols investigated
together with that of E2.
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small volume of water added and evaporated under vacuum before
freeze-drying. Freeze-dried DMEs were ground in a darkened room to
a fine homogeneous powder, which was stored in glass vials, covered
with aluminum foil, and placed in vacuum-sealed desiccators in the
dark at room temperature.
Cell Culture. COS-1 cells (ATCC) and estrogen-insensitive MDA-
MB-231 cells (38) (a kind gift from G. Haegemann, University of Gent,
Belgium) were maintained in DMEM supplemented with 10% (v/v)
fetal calf serum (FCS) and a penicillin (100 IU/mL) and streptomycin
(100 íL/mL) mixture (penicillin-streptomycin). The ERR and ERâ
positive MCF-7-BUS cells (38) (a kind gift from A. Soto, Tufts
University, U.S.) were maintained in DMEM supplemented with 5%
(v/v) heat inactivated FCS, but without antibiotics. All cells were
maintained in a humidified cell incubator set at 97% relative humidity
and 5% CO2 at 37 °C.
Transient Transfections and Whole Cell Binding Assays in
COS-1 Cells. COS-1 cells were plated at a density of 2  106 cells
per 10 cm tissue culture dish. Twenty-four hours after plating, COS-1
cells were transiently transfected with expression vectors for the ER
subtypes, pcDNA3-hERR (a kind gift from D. Harnish, Womens’s
Health Research Institute, Wyeth-Ayerst Research, U.S.) or pSG5-hERâ
(a kind gift from F. Gannon, European Molecular Biology Laboratory,
Heidelberg, Germany) and a filler vector, pGL2-basic (Promega Corp.,
Madison, WI). Two different transfections methods were used to
transfect the ER subtypes. The Fugene6 transfection reagent was used
for the hERR transfections, and the DEAE-Dextran transfection method
was used for hERâ transfections. The total DNA transfected for both
transfection protocols was 6 íg/10 cm dish that consisted of 0.72 íg
of receptor and 5.28 íg of empty vector. The Fugene6 transfection
protocol, used for hERR, was per the manufacturer’s instructions with
12 íL of Fugene6 reagent allowed to react with 6 íg of DNA. The
DEAE-Dextran transfection medium, used for hERâ, consisted of 5
mL of DMEM, pre-heated to 37 °C, 0.1 mM chloroquine (stock solution
100 mM), 6 íg of DNA, and finally 0.1 mg/mL DEAE-Dextran
solution (stock solution 10 mg/mL). Cells were incubated with the
DEAE-Dextran transfection medium for 1 h at 37 °C after which they
were shocked with 10 mL of pre-heated 10% DMSO-PBS for about
2 min. Finally, transiently transfected cells were incubated at 37 °C
overnight in DMEM supplemented with 10% FCS and 1% penicillin-
streptomycin mixture. The following day the transfected COS-1 cells
were pooled and seeded into 24-well tissue culture plates at a density
of 5  104 cells/well and incubated for 24 h. The next day the cells
were washed three times with 500 íL of PBS/well (pre-heated at 37
°C). This was followed by a 2-h incubation of the transfected cells
with 10-9 M radiolabeled estradiol (2,4,6,7-3H-17-â-estradiol from
Amersham, Cape Town, South Africa, with specific activity 87.0 Ci/
mmol and counting efficiency of 46%) and various concentrations,
ranging from 2.7  10-13 to 7.94  10-3 mg/mL, of unlabeled
competitors, that is, extracts and polyphenols (dissolved in DMSO) in
DMEM without phenol red and FCS. All assays included a total binding
point, which was in the presence of 0.1% DMSO, and E2 and genistein
as positive controls. After the 2 h incubation period, the cells were
immediately placed on ice, and further work was done at 4 °C. Cells
were washed three times with 1 mL of 0.2% bovine serum albumin-
PBS with an interval of 15 min between washes to remove free ligand.
Cells were then lysed with 50 íL of lysis buffer (0.2% (v/v) Triton,
10% (v/v) glycerol, 2.8% (v/v) Tris-phosphate-EDTA, and 1.44 mM
EDTA) per well. For effective lysis, plates were placed on a shaker
for approximately 15 min and thereafter allowed to freeze at -20 °C.
On thawing of samples, 5 íL of lysate was used for protein
determination using the Bradford method (39). Another 50 íL of lysis
buffer was added to the remaining lysate in the wells, and this was
transferred to scintillation vials to which 3 mL of scintillation fluid
(Quickszint FLOW 2; Zinsser Analytic, Cape Town, South Africa) was
added. Radioactivity of the assay samples was determined using a
Beckman LS 3801 Beta-scintillation counter. The protein concentrations
were used to normalize radioactivity readings, and results are expressed
as percentage of normalized control with total binding (in presence of
0.1% DMSO) taken as 100%. All binding experiments also included a
control for ligand depletion. The ligand depletion for all whole cell
ER binding experiments was less than 10%.
Transient Transfections and ERE-Containing Promoter Reporter
Assays in COS-1 Cells. The cells were transfected using the Fugene6
reagent as per the manufacturer’s instructions. For hERR transfection,
COS-1 cells (5  104 cells/well) were directly transfected in 24-well
dishes 24 h after plating. Briefly, 300 ng of total DNA/well, consisting
of 5 ng of hERR (pSG5-hERR, a kind gift from F. Gannon, European
Molecular Biology Laboratory, Heidelberg, Germany) expression
plasmid, 200 ng of ERE-containing promoter reporter construct
(ERE.vit2.luc, a kind gift from K. Korach, National Institute of
Environmental Health Science, U.S.), 5 ng of pCMV-â-galactosidase
(Stratagene, La Jolla, CA) for normalization of transfection efficiency,
and 90 ng of empty vector (pGL2-Basic) were used with 0.6 íL of
Fugene6 for hERR transfections. Cells were induced 24 h after
transfection. For hERâ transfections, COS-1 cells were plated at a
density of 2  106 cells/10 cm dish and transfected 24 h after plating.
A total of 9.6 íg of DNA consisting of 0.8 íg of hERâ (pSG5-hERâ,
also a gift from F.Gannon) expression plasmid, 8 íg of ERE.vit2.luc,
and 0.8 íg of pCMV-â-galactosidase were transiently transfected using
19.2 íL of Fugene6 reagent/dish. The following day cells were pooled
and seeded at a density of 5  104 cells per well into 24-well tissue
culture plates and incubated for 24 h before induction. Transfected cells
were induced for 24 h with various concentrations of polyphenol
compounds or DMEs (dissolved in DMSO) ranging from 2.7  10-13
to 7.94  10-3 mg/mL. All assays included a negative control, which
consisted of 0.1% (v/v) DMSO only, and E2 and genistein as positive
controls. After induction the medium was aspirated, 50 íL of lysis
buffer (Tropix Inc. (Applied Biosystems, Bedford, MA)) was added,
and cells were frozen at -20 °C overnight. Luciferase assay reagent
(Promega Corp., Madison, WI) was used to quantify luciferase activity
in accordance with the manufacturer’s instructions. Briefly, 10 íL of
cell lysate was allowed to react with 50 íL of luciferase assay reagent.
The relative light units (RLU’s) were measured using the Veritas
luminometer. A further 5 íL of cell lysate for each sample was used
to measure â-galactosidase activity with the â-galactosidase chemilu-
minescent Galacto-Star reporter gene assay system for mammalian cells
(Tropix Inc. (Applied Biosystems, Bedford, MA)). Luciferase RLU’s
were normalized with â-galactosidase readings, and results were
expressed as normalized fold induction with negative controls (0.1%
DMSO) taken as 1.
MTT Cell Proliferation Assay. MCF-7 BUS and MDA-MB-231
cells were plated at a density of 2500 cells/well in 96-well plates and
incubated for 24 h. The cells were then washed with 200 íL of PBS,
pre-warmed to 37 °C, followed by steroid starving for 72 h through
addition of DMEM pre-warmed to 37 °C without phenol red, but
supplemented with 5% charcoal stripped FCS and a 1% penicillin-
streptomycin mixture. On day five the medium was aspirated and cells
were induced with increasing concentrations, ranging from 2.7  10-13
to 7.94  10-3 mg/mL, of test compounds or DMEs (in DMSO)
prepared in DMEM without phenol red, but supplemented with 5%
charcoal stripped FCS and a 1% penicillin-streptomycin mixture. Cells
were then incubated for 48 h whereafter the colorimetric MTT (3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay was pre-
formed. The MTT assay entails that 5 h before the end of the incubation
period the assay medium is changed to unsupplemented DMEM without
phenol red whereafter 20 íL of MTT solution (5 mg/mL) is added to
each well. Cells were incubated for 5 h at 37 °C, the medium was then
removed, and 200 íL of solubilization solution (DMSO) was added to
each well. The DMSO was pipetted up and down in the well to dissolve
crystals until a uniform purple color had formed. The plate was then
placed in a 37 °C incubator for 5 min, and the absorbance was read at
540 nm in a micotiter plate reader (Titertek Multiskan Plus, Titertek
Instruments Inc., Huntsville, AL). All assays included a negative control,
which consisted of 0.1% (v/v) DMSO only, and E2 and genistein as
positive controls. Results are expressed as fold induction with negative
controls (0.1% DMSO) taken as 1.
Co-treatment by both E2 (10-9 M) and the polyphenols (10-5 M
except for genistein, which was tested at 10-7 M) or DME (9.8 íg/
mL) was investigated. In addition, induction with test compounds and
DME was investigated in the presence of 10-9 M ER antagonist, ICI
182,780.
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Competitive SHBG Binding Assay. Displacement of 20  10-9
M 3H-E2 by test compounds and DME from SHBG was determined
by the competitive SHBG binding assay as adapted from the method
used by Hammond and La¨hteenma¨ki (40). Pooled human pregnancy
serum with a SHBG concentration of 408.6  10-9 M was diluted
(1:100) with dextran-coated charcoal (DCC; 1.25 g of activated charcoal
Norit CA1 and 0.125 g of T70 dextran were added to 500 mL of 0.02%
gelatin-PBS mixture). Briefly, 20 íL of pregnancy serum was added
to 2 mL of DCC-slurry and mixed at room temperature for 30 min.
Following centrifugation at 5000g at room temperature, the supernatant
was collected, and 100 íL of diluted serum was added to 100 íL each
of unlabeled E2 (10-5 M), polyphenols (10-5 M), DME (9.8 íg/mL),
and DMSO vehicle only (negative control) as competitors. This was
followed by the addition of 100 íL of PBS containing 60  10-9 M
3H-E2. The mixture was allowed to incubate for 1 h at room temperature
followed by 15 min incubation in an ice-water bath kept at 4 °C. The
unbound 3H-E2 was then removed by incubating with 750 íL of ice-
cold DCC-slurry for 10 min followed by centrifugation at 3000g for 3
min at 4 °C. The supernatant was quickly decanted, and a constant
volume (750 íL) was added to scintillation vials containing 3 mL of
scintillation fluid. Radioactivity was read on the Beckman LS 3801
scintillation counter. Results are expressed as the percentage 20  10-9
M 3H-E2 displaced from SHBG. The total bound, that is, in the presence
of vehicle (DMSO) only, represents 0% 3H-E2 displaced from the
SHBG.
HPLC and LC-MS Analysis. DAD-HPLC analysis of the extracts
was carried out according to Verhoog et al. (22) on a Phenomenex
Synergy MAX-RP 80A (C12 reversed-phase with TMS end-capping)
column using an aqueous acetic acid-acetonitrile gradient with
quantification at 280 nm. For further confirmation of peak identity,
the extracts were subjected to LC-MS analysis, using a Waters API
Quattro Micro apparatus with a Waters 2690 quaternary HPLC pump
and 996 photodiode array detector, and electrospray ionization operating
in the negative mode. The operation conditions entailed: desolvation
gas temperature 350 °C; nebulizing gas (nitrogen) flow rate, 500 L/h;
source temperature, 120 °C; capillary voltage, 3500 V; and cone voltage,
25 V. Separation conditions was the same as for the HPLC analysis,
except that the 2% acetic acid was replaced by 0.1% formic acid as
the mobile phase. The same authentic standards of compounds
tentatively identified by DAD-HPLC were analyzed for further
confirmation of peak identity.
Data Manipulation and Statistical Analysis. The GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego, CA) was
used for graphical representations and statistical analysis. One-way
ANOVA and Dunnett’s multiple comparisons’ test as post-test were
used for statistical analysis. P-values are represented as follows:
statistically different from E2 by * (P < 0.05), ** (P < 0.01), and ***
(P < 0.001) and statistically different from genistein by # (P < 0.05),
## (P < 0.01), and ### (P < 0.001). Nonlinear regression and one-site
competition curve fitting were used to graph the data from the whole
cell binding assays and to determine IC50 values. The relative binding
affinity (RBA) is expressed relative to that of E2 (100%) and was
calculated as follows: 100  IC50 (E2)/IC50 (test compound). The Ki
values were determined from the IC50 values and Kd for E2 according
to the equation by Cheng and Prusoff (41). Nonlinear regression and
sigmoidal dose response curve fitting were used to graph the data from
the ERE-containing promoter reporter and proliferation experiments
and to determine fold induction and EC50. For all experiments, unless
otherwise indicated, the error bars represent the SEM of three
independent experiments done in triplicate.
RESULTS
Binding to ER Subtypes. All polyphenols were able to bind
to both ER subtypes, except for the xanthone, mangiferin (Table
2). The order of potency for hERR (IC50 values) was E2 .
formononetin > genistein > naringenin . luteolin. Generally,
all polyphenols, including genistein, bound to ERR displayed
significantly (P < 0.01) weaker binding than E2 with RBA
values ranging from 0.93% for formononetin to 0.003% for
luteolin. The order of potency for hERâ was E2 > genistein .
luteolin > formononetin ) naringenin. All polyphenol IC50
values for binding to hERâ were significantly (P < 0.01) lower
than those for E2 and genistein with RBA values ranging from
0.48% for naringenin to 0.52% for luteolin. All of the polyphe-
nols that bound, except formononetin, had a higher binding
affinity for the hERâ, in contrast to E2 that had a slightly higher
affinity for ERR. Genistein, especially, had a very high binding
affinity (Ki value ) 1.01  10-9 M) for hERâ and showed a
strong preference for this subtype (Ki â/R ratio ) 42.7).
Formononetin, similarly to E2, had a slight binding preference
(Ki â/R ratio ) 0.25) for hERR.
The DME, even though from the same species, portrayed
large variations in binding to the ER subtypes with only the
two extracts from the P104 harvesting able to significantly (P
< 0.01) compete with 3H-E2 for binding to the ER subtypes
(Table 2). O P104 displayed a lower potency than N P104.
The binding potencies measured for hERR and hERâ of N P104
and O P104 were significantly different (P < 0.01) from those
of E2 and genistein. Although N P104 in comparison to O P104
Table 2. Whole Cell Competitive Binding by E2, Polyphenols, and DME to the hER Subtypes
IC50 (mg/mL)a RBAb (%) Kid (M)test
compounds hERR hERâ hERR hERâ
â/R of
RBAc hERR hERâ â/R of Kic
E2 3.7 × 10-7 (3.63)##e 7.3 × 10-7 (4.74) 100 100 1 0.37 × 10-9 M (5.44) 1.17 × 10-9 M (5.01) 0.3
genistein 4.2 × 10-5 (37.32)**f 9.0 × 10-7 (1.23) 0.73 81.11 111.10 43.1 × 10-9 M (8.99)* 1.01 × 10-9 M (4.98) 42.7
luteolin 1.5 × 10-2 (4.88)**## 1.4 × 10-4 (3.07)**## 0.00 3 0.52 173.35 12.20 × 10-6 M (25.61)** 0.39 × 10-6 M (8.79)** 31.3
formononetin 4.1 × 10-5 (4.59)** 1.5 × 10-4 (0.45)**## 0.93 0.48 0.52 34.51 × 10-9 M (9.51)* 0.14 × 10-6 M (7.52)** 0.25
naringenin 3.9 × 10-4 (8.33)** 1.5 × 10-4 (2.88)**## 0.09 7 0.48 4.95 0.27 × 10-6 M (0.79)** 0.11 × 10-6 M (10.46)** 2.5
mangiferin NBg NB NB NB NB NB NB NB
N P104 2.1 × 10-4 (4.88)**## 1.3 × 10-1 (26.28)**## 0.18 0.0006 0.003
O P104 5.9 × 10-4 (18.07)**## 2.3 × 10-1 (19.24)**## 0.05 0.0003 0.006
N P105 NB NB NB NB NB
O P105 NB NB NB NB NB
N P122 NB NB NB NB NB
O P122 NB NB NB NB NB
a The IC50 and CV (coefficient of variation) values are calculated from the log IC50 values from at least three independent experiments. b RBA or relative binding affinity
is expressed relative to that of E2 (100%) and was calculated as follows: 100 × IC50 (E2)/IC50 (test compound). c â/R ratio of RBA or Ki is such that the ratio is >1 for
compounds having a higher affinity for hERâ than hERR, < 1 if compounds have a higher binding affinity for hERR than hERâ, and equal to 1 for compounds having a
similar affinity for both ER subtypes. The â/R ratio of RBA is calculated by RBA hERâ/RBA hERR, and the â/R ratio of Ki is calculated by Ki hERR/Ki hERâ. d Ki values
were determined from the Kd of E2. The Kd values of E2 for hERR and hERâ were 0.37 × 10-9 ± 0.38 M and 1.17 × 10-9 ± 0.18 M, respectively. e Statistically different
from genistein with “#” representing P < 0.05, “##” representing P < 0.01, and “###” representing P < 0.001. f Statistically different from E2 with “*” representing P < 0.05, “**”
representing P < 0.01, and “***” representing P < 0.001. g NB ) non-binder polyphenols or extracts were unable to displace 3H-E2 from ER subtype.
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had higher potencies for both ER subtypes, they were not
significantly (P > 0.05) different from each other (statistical
data not shown). In contrast to most of the polyphenols
investigated, formononetin and mangiferin excluded, P104 had
a higher RBA and a stronger preference (RBA â/R ratio ) 0.003
and 0.006 for N P104 and O P104, respectively) for the ERR
subtype.
Transactivation of an ERE-Containing Promoter Re-
porter Construct via the hER Subtypes. E2 transactivated
hERR and hERâ with similar potencies, while the polyphenols
generally, with the exception of luteolin, transactivated more
potently via hERâ (Table 3). The order of potency via hERR
was E2 . genistein . formononetin ) luteolin, while via hERâ
it was E2 > genistein > formononetin > naringenin > luteolin.
The potency of E2 via hERR was significantly different (P <
0.01) from that of genistein, luteolin, and formononetin, while
only the potency of genistein was significantly different (P <
0.05) from that of luteolin. The potency of E2 via hERâ was
significantly (P < 0.01) higher than that of the polyphenols,
except genistein, while the potency of genistein, however, was
only significantly different (P < 0.05) from that of luteolin and
naringenin, but not formononetin. The transactivational efficacy
of the various polyphenols via hERR was luteolin > formonon-
etin > genistein > E2, with luteolin and formononetin not
significantly different (P > 0.05) from E2 and genistein, with
the latter not statistically different (P > 0.05) from each other.
The transactivational efficacy of the various polyphenols via
hERâ did not differ significantly (P > 0.05) from each other
or from that of E2 and genistein (Table 3). Although both E2
and genistein, in contrast to the polyphenols tested, displayed a
relatively high potency for both binding and ERE-containing
promoter reporter assays via hERâ, the transactivational efficacy
was approximately similar for all polyphenols and E2 (P > 0.05).
The DMEs were only able to induce the ERE-containing
promoter reporter construct via the hERâ, but not via hERR
(Table 3) despite the fact that some extracts (from the P104
harvesting) were able to displace 3H-E2 from both hERâ and
hERR, with higher RBAs for hERR than for hERâ (Table 2).
The order of potency (EC50) of E2, genistein, and extracts was
as follows for hERâ: E2 > genistein > O P122 > O P104 >
N P104 > O P105 > N P122 > N P105 (Table 3). Potencies
of extracts, via hERâ, were not significantly (P > 0.05) different
from that of E2, except for N P104 and O P105, while none of
the extracts were significantly different from genistein. The
efficacy of the extracts, via hERâ, was not significantly different
(P > 0.05) from that of either genistein or E2.
Proliferation of Breast Cancer Cells. All polyphenols
investigated were able to induce cell proliferation of the MCF-
7-BUS cells in a dose-dependent manner with the order of
potency being E2 . naringenin > genistein > luteolin >
formononetin > mangiferin (Table 4). All of the potencies of
the polyphenols were significantly different (P < 0.05) from
that of E2 but not significantly (P > 0.05) different from that
of genistein. The order of efficacy for the cell proliferation of
the MCF-7-BUS cells was genistein > E2 > naringenin >
mangiferin > formononetin > luteolin (Table 4). None of the
efficacy values determined for the polyphenols were signifi-
cantly (P > 0.05) different from that of E2 or genistein except
for luteolin and formononetin (P < 0.01). Neither the polyphe-
nols nor E2 were able to induce significant proliferation of the
MDA-MB-231 cells (Table 4).
DMEs from harvestings P104 and P105 were able to induce
cell proliferation of both human breast cancer cells, whereas
DMEs from harvesting P122 were unable to induce proliferation
of either of the two cell lines tested (Table 4). The rank order
of potency (Table 4) in MCF-7-BUS cells was as follows: E2
. genistein > N P104 > N P105 > O P104 > O P105. The
potency of the DMEs in MCF-7-BUS cells (Table 4) was
significantly (P < 0.01) lower than that of E2 with only O P104
and O P105 having a significantly (P < 0.05) lower potency
than genistein. The rank order of efficacy (Table 4) was as
follows: genistein > O P104 > E2 > N P104 > N P105 > O
P105. The efficacy of the DMEs in MCF-7-BUS cells was not
significantly (P > 0.05) different from that of E2 or genistein
with the exception of O P105, which was significantly (P <
0.05) different from that of genistein.
Similar to results with MCF-7-BUS cells, P104 and P105
were able to induce, albeit to a lesser extent, cell proliferation
of the estrogen-insensitive MDA-MB-231 cell line (Table 4).
However, P122, E2, and genistein were unable to induce
proliferation. The rank order of potency (Table 4) was as
follows: O P104 > N P105 > O P105 > N P104. The potency
values for the extracts were not significantly (P > 0.05) different
from each other (statistical data not shown). The rank order of
efficacy (Table 4) was as follows: N P105 > N P104 > O
Table 3. Potency (EC50) and Efficacy (Maximal Fold Induction) Values As Determined from Transactivation of an ERE-Containing Promoter Reporter




(maximal fold induction)test compounds
or DME hERR hERâ hERR hERâ
E2 3.70 × 10-7 (0.49)b##c 1.39 × 10-7 (4.99) 1.3 (33.97) 2.34 (6.48)
genistein 9.03 × 10-5 (8.15)** 1.06 × 10-6 (4.93) 1.77 (14.90) 2.76 (17.18)
luteolin 1.97 × 10-3 (4.9)**d# 3.53 × 10-3 (38.69)**##d 2.41 (26.57) 3.69 (48.22)
formononetin 1.01 × 10-3 (4.36)** 4.29 × 10-5 (5.53)** 2.18 (17.45) 2.20 (18.42)
naringenin N/A 1.04 × 10-4 (4.68)**# N/A 2.99 (33.94)
mangiferin N/A N/Ae N/A N/A
N P104 N/A 1.51 × 10-5 (22.60)* N/A 2.44 (36.78)
O P104 N/A 1.18 × 10-5 (21.36) N/A 2.39 (21.11)
N P105 N/A 9.20 × 10-5 (12.31) N/A 1.63 (3.25)
O P105 N/A 2.93 × 10-5 (22.66)* N/A 2.53 (62.77)
N P122 N/A 6.90 × 10-5 (0.21) N/A 1.90 (20.52)
O P122 N/A 2.48 × 10-6 (0.59) N/A 1.94 (27.49)
a EC50 values calculated from the log EC50 values of three independent experiments given as the mean (CV). b CV (coefficient of variation) calculated from the log EC50
of at least three independent experiments performed in triplicate. c Statistically different from genistein with “#” representing P < 0.05, “##” representing P < 0.01, and “###”
representing P < 0.001. d Statistically different from E2 where “*” represents P < 0.05 and “**” represents P < 0.01. e N/A: test compound or DME did not induce the
ERE-containing promoter reporter gene construct via the indicated hER subtype.
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P104 > O P105. None of the efficacies were significantly
different from each other (statistical data not shown).
To establish whether induced cell proliferation was ER
dependent, cells were co-treated with an ER antagonist, ICI 182,-
780. In MCF-7 BUS cells, co-treatment with 1  10-9 M ICI
182,780 reduced the response induced by all polyphenols
(Figure 2A), DMEs (Figure 3A), and E2, suggesting that the
proliferation response in these cells is ER-dependent as has been
previously suggested (42, 43). Similarly, in the MDA-MB-231
cells, ICI 182,780 reduced the minimal induction by all of the
polyphenols (Figure 2B) and E2 to that of the level of the
control. Induction by the DME in MDA-MB-231 cells, however,
was only partially reversed by ICI 182,780 in the case of P104
and P105, while in the case of P122 the antagonist appeared to
stimulate induction (Figure 3B).
In addition, the effect of the polyphenols or C. genistoides
DMEs on E2-induced proliferation in MCF-7 BUS cells was
investigated. Physiologically more relevant, this would establish
how the polyphenols and extracts would react in the presence
of the endogenous ligand. E2 proliferation in MCF-7-BUS cells
was significantly (P < 0.05) prevented by co-treatment with
all of the polyphenols, except mangiferin (Figure 4A) and all
of the DMEs (Figure 4B), including P122, despite the fact that
P122 did not induce cell proliferation on its own (Table 4).
The polyphenols, genistein, luteolin, formononetin, and narin-
genin, and the DME, therefore antagonized E2-induced prolif-
eration and appeared to act as anti-estrogens in the presence of
1  10-9 M E2.
Binding to SHBG and Displacement of E2. The percentage
of 3H-E2 displaced from SHBG by the polyphenols (Figure 5A)
and C. genistoides DME (Figure 5B) was significant (P < 0.05),
except in the case of mangiferin. Displacement by naringenin,
which was higher than that of genistein, was not significantly
different (statistical data not shown) from that of E2, similar to
what was found by others (44). In addition, N P104 and O P122
were also as effective as E2 in competing with 3H-E2 for binding
to the SHBG (statistical data not shown).
HPLC and LC-MS Analysis. The polyphenols quantified
in the C. genistoides DME included formononetin, luteolin,
naringenin, and mangiferin, as their estogenicity was tested in
this study. In addition, these polyphenols had also been shown
to be present in C. intermedia and C. subternata (2, 3). Levels
of isomangiferin, eriocitrin, narirutin, hesperidin, hesperetin, and
isosakuranetin were also evaluated as they had been shown to
be present in some Cyclopia species, although a previous study
(22) showed that only eriocitrin, narirutin, and eriodictyol bound
to the ERâ. Peaks corresponding to luteolin, eriocitrin, and
narirutin were identified on the HPLC chromatogram (Figure
6). However, the peaks eluting at retention times similar to those
of eriocitrin and narirutin are of unknown compounds as their
mass was different from that of the pure standards (Table 5).
Their UV-vis spectra and retention times suggest that these
Table 4. Potency (EC50) and Efficacy (Maximal Fold Induction) Values Determined for E2, Various Polyphenols, and DME from Cell Proliferation












E2 2.79 × 10-10 (2.92)b##c 2.14 (8.46) N/Ad N/A
genistein 1.02 × 10-6 (7.56)**e 2.35 (10.57) N/A N/A
luteolin 2.54 × 10-6 (15.77)** 1.26 (2.52)**## N/A N/A
formononetin 1.48 × 10-5 (14.90)** 1.38 (4.15)**## N/A N/A
naringenin 3.27 × 10-8 (1.60)* 2.08 (4.15) N/A N/A
mangiferin 3.13 × 10-4 (31.07)** 1.72 (3.44) N/A N/A
N P104 1.98 × 10-6 (7.34)** 2.07 (17.05) 2.47 × 10-9 (2.66) 1.62 (19.31)
O P104 1.34 × 10-4 (17.64)**## 2.17 (18.21) 1.39 × 10-10 (18.87) 1.59 (25.56)
N P105 6.52 × 10-6 (25.71)** 1.82 (31.08) 2.62 × 10-10 (16.81) 1.81 (32.24)
O P105 1.47 × 10-4 (2.45)**# 1.50 (13.37)# 2.79 × 10-10 (17.23) 1.38 (35.85)
N P122 N/Ae N/A N/A N/A
O P122 N/A N/A N/A N/A
a EC50 values calculated from the log EC50 values of three independent experiments given as the mean (CV). b CV or coefficient of variation calculated from the log EC50
of at least three independent experiments performed in triplicate. c Statistically different from genistein with “#” representing P < 0.05 and “##” representing P < 0.01. d N/A
not applicable as it could not be determined. e Satistically different from E2 with “*” representing P < 0.05 and “**” representing P < 0.01.
Figure 2. Cell proliferation of polyphenols and E2 in (A) MCF-7-BUS and
(B) MDA-MB-231 breast cancer cells. Co-treatment with ER antagonist,
ICI 182,780, identifies if induced response is ER-dependent. All compounds
were tested at 10 × 10-6 M except for E2 and genistein, which were
investigated at 1 × 10-9 and 0.1 × 10-6 M, respectively. The control
represents vehicle (DMSO) only. Statistical analysis compared induction
by a specific compound in the absence and presence of the ER antagonist
using two-tailed t tests (# ) P < 0.05; ns ) P > 0.05 or not significantly
different). Abbreviations: genistein (Gen), luteolin (Lut), formononetin
(Form), naringenin (Nar), and mangiferin (Mang).
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two compounds are flavanone glycosides with ìmax between 280
and 290 nm. Three other unknown peaks were observed at
retention times of 3.7, 10.0, and 16.5 min (Figure 6). The latter
two peaks also had UV-vis spectra similar to those of
flavanones.
DISCUSSION
The presence of the phytoestrogens, formononetin, naringenin,
and luteolin, in Cyclopia, coupled to anecdotal evidence of its
use for the treatment of menopausal symptoms, led to the
investigation of phytoestrogenic activity in Cyclopia as a
potential source of phytoestrogens indigenous to South Africa
(2, 3). A previous study (22) identified C. genistoides, among
the four species of Cyclopia tested, as the most consistent in
demonstrating phytoestrogenic activity through binding to the
ER subtypes. Thus, in the present study, DMEs from unfer-
mented C. genistoides were chosen for further in-depth study
using several estrogenic endpoints to establish and evaluate
estrogenicity and to compare estrogenicity with that of the
known phytoestrogen, genistein, and the natural ligand, E2.
Luteolin, formononetin, naringenin, and mangiferin were in-
cluded in the study as plant polyphenols previously shown to
be present in Cyclopia species (2, 3, 45), and all, except
mangiferin, demonstrated ability to bind to both ER subtypes
(22). Mangiferin was chosen as it is the most abundant
polyphenol present in honeybush (45, 46).
The C. genistoides extracts all induced transactivation via
hERâ, but not hERR, despite the fact that only one harvesting,
P104, bound to the ER (Tables 2 and 3). Proliferation studies
in MCF-7 cells (Table 4) showed that all but one harvesting,
P122, induced proliferation with potency similar to that of
genistein.
By using the ER antagonist, ICI 182,780, proliferation by
polyphenols in MCF-7 cells was established to be via the ER
(Figure 2). MCF-7 cell proliferation induced by DMEs was
only partially, although significantly, reversed by ICI 182,780
(Figure 3A), while all of the extracts, except P122, induced
cell proliferation in the MDA-MB-231 cells (Figure 3B), which
could not be effectively blocked with the ER antagonist. This
suggests that, in addition to an ER-dependent mechanism of
action, the extracts may also display an ER-independent
mechanism of action. Confirmation of this would, however,
require further study.
In addition to measuring and validating phytoestrogenic
activity, SHBG binding was also measured. All of the polyphe-
nols, except mangiferin, and DME were able to significantly
(P < 0.01) compete with 3H-E2 for binding to SHBG implying
that they can be transported in the bloodstream through binding
to SHBG, which would consequently decrease metabolic
clearance rate and subsequent excretion as was proposed for
Figure 3. Cell proliferation of DME, genistein, and E2 in (A) MCF-7-BUS
and (B) MDA-MB-231 breast cancer cells. Co-treatment with ER
antagonist, ICI 182,780, identifies if induced response is ER-dependent.
All extracts were investigated at 9.8 íg/mL, and E2 and genistein at 1 ×
10-9 and 10 × 10-6 M, respectively. The control represents vehicle
(DMSO) only. Statistical analysis compared induction by a DME in the
absence and presence of the ER antagonist using two-tailed t tests (# )
P < 0.05; ns ) P > 0.05 or not significantly different). Abbreviations:
genistein (Gen).
Figure 4. Effect of (A) various polyphenols and (B) C. genistoides DME
on E2 (1 × 10-9 M)-induced proliferation of MCF-7-BUS. All polyphenols
were investigated at 10 × 10-6 M, and the DME was investigated at 9.8
íg/mL. Statistical analysis compared cell proliferation induced by 1 ×
10-9 M E2 only with that induced by 1 × 10-9 M E2 plus polyphenols or
DME using one-way ANOVA with Dunnet’s multiple comparisons’ post
test (*P < 0.05; **P < 0.01). Abbreviations: genistein (Gen), luteolin (Lut),
formononetin (Form), naringenin (Nar), and mangiferin (Mang).
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endogenous estrogens (37, 47). For future studies, it would be
interesting to investigate whether extracts of C. genistoides and
relevant polyphenols would increase the secretion of SHBG
from liver cells as it has been shown that phytoestrogens can
increase the synthesis of SHBG (48, 49), and an increase in the
concentration of SHBG would affect the amount of biologically
free steroid (36, 47).
Two attributes of phytoestrogens, weak estrogenicity and
preference for ERâ, have been linked to their beneficial health
effects (7, 50-52). Both attributes are to be discussed here as
they pertain to the results obtained with C. genistoides extracts.
To facilitate evaluation, we will also compare activities with
that of E2, the endogenous estrogen linked to both adverse (53,
54) and beneficial health effects (53), and genistein, a well-
studied phytoestrogen (5).
It has been suggested that the weak estrogenic potential of
phytoestrogens may contribute to health-promoting effects such
as protecting against the onset of osteoporosis, cardiovascular
disease, and certain hormone dependent cancers (7, 50-52).
The DMEs and polyphenols tested were consistently less (102-
105 times) potent than E2 (Tables 2-4). Other studies have
shown similar decreases in potencies for genistein as compared
to E2 in ER binding, transactivation, and proliferation studies
(27, 55, 56).
The hERâ is believed to be a modulator of hERR activity as
it inhibits proliferation of breast cancer cells and immature rat
uterus (34, 57, 58). It has been shown, in ERR containing T47D
breast cancer cells, that ERâ inhibits E2-induced cell prolifera-
tion if the cells are transfected with ERâ to such an extent that
the mRNA levels of the two ER subtypes were equal (34). These
findings would suggest that either ERâ has an anti-proliferative
effect on breast cancer cells or it quenches ERR activity (34,
59). Competitive binding with both ER subtypes was investi-
gated as numerous studies have shown that phytoestrogens bind
preferentially to the ERâ (26, 27, 60, 61). The present study
indeed demonstrated that the phytoestrogens, genistein, luteolin,
and naringenin, but not formononetin, bind with a higher affinity
to the ERâ subtype (Table 2), confirming results by others (25,
26, 60-63). Formononetin, however, had a slight binding
preference for hERR, which is contrary to what others have
shown (61, 62) and differs from what is found for most
phytoestrogens (26, 27, 60).
Not only did all polyphenols, except mangiferin, bind to ERâ,
they also preferentially transactivated via ERâ (Table 3) and
induced cell proliferation of MCF-7-BUS cells (Table 4). Of
the three harvestings of C. genistoides tested, only one, P104,
bound to the ER subtypes. Unlike the phytoestrogens, however,
it bound preferentially to the hERR, like E2 (Table 2). Other
plant extracts such as red wine, Ginkgo biloba, kudzu root, and
red clover extracts have been shown to have binding affinity
for both ER subtypes, but with a higher binding affinity for
ERâ (62, 64-66). It was therefore not expected that the C.
genistoides methanol extracts would preferentially bind to the
hERR. However, despite binding preferentially to the hERR and
binding to the hERâ with a potency significantly (P < 0.001)
lower than that of either E2 or genistein, P104 was able to
transactivate an ERE-containing reporter promoter via hERâ,
but not via ERR, with a potency similar to that of E2 and
genistein and to induce MCF-7 cell proliferation with a potency
similar to that of genistein but significantly (P < 0.01) lower
than that of E2 (Table 4). In addition, although P105 and P122
were unable to compete with 3H-E2 for binding to hERâ, both
Figure 5. Competitive binding of (A) polyphenols and (B) C. genistoides
DME to SHBG in DCC stripped human pregnancy serum incubated with
20 × 10-9 M 3H-E2. Polyphenols and E2 were used at a concentration of
10-5 M and the extracts at a concentration of 9.8 íg/mL. The control in
both represents vehicle (DMSO) only. For statistical analysis, one-way
ANOVA was used with Dunnet’s multiple comparisons’ post test comparing
percentage 3H-E2 displaced to control. P-values are represented as
follows: P < 0.05 by *, P < 0.01 by **.
Figure 6. Typical HPLC chromatogram of a DME showing the polyphenols
co-eluting at retention times similar to those of known standards: (a)
unknown at 3.7 min, (b) mangiferin, (c) isomangiferin, (d) unknown
flavanone glycoside at 10.0 min, (e) unknown flavanone glycoside at 13.4
min, (f) unknown flavanone glycoside at 16.0 min, (g) unknown flavanone
glycoside at 16.5 min, (h) hesperidin, and (i) luteolin.
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extracts were able to induce transactivation via the hERâ, but
not the ERR, and P105 was also able to induce proliferation.
These results seem to suggest that the C. genistoides extracts
are disproportionably effective in activating the hERâ. Further
evidence for the activity of the extracts through hERâ comes
from their ability to antagonize E2-induced cell proliferation of
MCF-7-BUS cells (Figure 4B), also seen with the polyphenols,
genistein, luteolin, formononetin, and naringenin (Figure 4A)
and as shown by others (67, 69, 70). Polyphenols and extracts,
which are able to act preferentially via hERâ, could be of
physiological importance as this could play a role in the
prevention of excessive cell proliferation, which is associated
with cancer formation (31).
Investigations into the estrogenic activity of other plant
extracts have yielded results similar to those found in the present
study. Kudzu root, soybean, red clover, and alfalfa sprout
displayed agonist activity through the ERE-containing promoter
reporter assays by activating both ERR and ERâ, with prefer-
ential activation of ERâ observed (66). In addition, extracts from
Moghania philippinensis (71), kudzu root, red clover, alfalfa
sprout, and soybean (66) could also induce MCF-7 cell
proliferation. Additionally, Ginkgo biloba extracts were shown
to induce proliferation of MCF-7 cells that is ER-dependent as
the response could be blocked with an ER antagonist (65, 66).
The Ginkgo biloba extracts could, however, not induce cell
proliferation of MDA-MB-231 cells (65). On the other hand,
methanol extracts from M. philipinensis have previously been
shown to antagonize MCF-7 cell proliferation induced by E2
(71).
HPLC and LC-MS analysis (Table 5 and Figure 6) shows
that of the polyphenols tested for estrogenicity only luteolin is
present in detectable quantities. The amount of luteolin present
(0.096-0.106 g/100 g) is, however, too low to explain the fact
that in MCF-7-BUS cell proliferation, for example, two DMEs
(N P104 and N P105) show potencies similar to that of luteolin.
Five unknown peaks (a, d-g) are observed in the HPLC
chromatogram. Of these, four (d-g) are most probably unknown
flavanone glycosides based on their UV-vis spectra (ìmax) and
relative retention time to the other flavanone glycoside. The
fact that the DME behaved differently from the polyphenols
tested in that they induced proliferation via the estrogen-
insensitive MDA-MB-231 cell line, which was only partially
reversed by the ER antagonist ICI 182,780, suggests that these
unknown peaks may represent novel compounds present in the
DMEs with biological activity that differs from that of the
polyphenols tested. Confirmation of the estrogenic potential of
these unknown peaks awaits further study.
To summarize, the present study showed that the polyphenols,
luteolin, formononetin, and naringenin, present in Cyclopia spp.
and some DMEs from C. genistoides are estrogenic in vitro
through binding to both ER subtypes, inducing transactivation
via hERâ, and by inducing cell proliferation of the estrogen
sensitive MCF-7-BUS cells. Proliferation of the estrogen-
insensitive MDA-MB-231 cell line was, however, only stimu-
lated by DMEs. Although the present study showed that C.
genistoides is a potential source of phytoestrogens, caution
should, however, be exercised as variation within the species
does exist. DME from only one harvesting (P104) was able to
displace 3H-E2 from the ER subtypes, and DMEs of only two
harvestings (P104 and P105) were able to induce proliferation
of the MCF-7-BUS cells, while all three DMEs (P104, P105,
and P122) portrayed estrogenicity through induction of the ERE-
containing promoter reporter via ERâ. The variations in
estrogenicity may be ascribed to polyclonal plant material and
stress factors such as temperature and soil requirements (72,
73). Therefore, each individual batch of plant material available
at this stage in the industry would probably have to be screened
if it is to be used to prepare a nutraceutical.
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